Cardiovascular DiseasesNCT06808282
Effects of Dark Chocolate on the Risk Factors of Cardiovascular Diseases
A study testing White chocolate and Dark chocolate in people with Cardiovascular Diseases, run by San Diego State University at 1 site in United States.
Trial summary
Cardiovascular disease (CVD) is the number one cause of death in the US. Epidemiologic evidence supports that antioxidant-rich diets promote health and attenuate or delay the onset of CVD. Cocoa and chocolate products have among the highest antioxidant concentrations compared to other antioxidant food sources. Read more about this study
- Who is it for?
- Ages 21 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Diseases
- What is being tested?
- White chocolate and Dark chocolate
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2011to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Generally healthy subjects
Who cannot join
- Smoker
- Pregnant woman
- Lactose intolerance
- Required dietary supplement use
- Required medication of metabolic disorders
- Allergy to cacao
Trial locations and contacts
1 site in 1 country.
United States1 site
San Diego State University
San Diego, California, 92182
About this study
Cardiovascular disease (CVD) is the number one cause of death in the US. Epidemiologic evidence supports that antioxidant-rich diets promote health and attenuate or delay the onset of CVD. Cocoa and chocolate products have among the highest antioxidant concentrations compared to other antioxidant food sources. The objective of this study is to examine the effects of regular dark chocolate, bloomed dark chocolate, and white chocolate on cardiovascular health markers.
- Conditions
- Cardiovascular Diseases
- Being tested
- White chocolate, Dark chocolate
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
White chocolateOther
To determine the effects of white chocolate consumption on risk factors of cardiovascular diseases
Dark chocolateOther
To determine the effects of dark chocolate consumption on risk factors of cardiovascular diseases
| Study group | Role | What they receive |
|---|---|---|
| White chocolate | Active comparator | Subjects consume 50g of white chocolate daily for 15 days. Receives: Other: White chocolate |
| Dark chocolate | Experimental | Subjects consume 50g of dark chocolate daily for 15 days. Receives: Other: Dark chocolate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of systolic and diastolic blood pressure
Change of systolic and diastolic blood pressure will be determined to examine effects of dark chocolate consumption vs white chocolate.
Measured: Baseline and Day 15
Change of skin blood flow level
Change of skin blood flow level will be determined using Laser Doppler Flowmetry to examine effects of dark chocolate consumption vs white chocolate. Laser Doppler flowmetry is an optical technology widely used in research to measure blood flow. It is a non-invasive, painless technique for studying microcirculatory changes in tissue.
Measured: Baseline and Day 15
Change of HDL cholesterol level
Change of blood cholesterol level will be determined to examine effects of dark chocolate consumption vs white chocolate.
Measured: Baseline and Day 15
Change of antioxidant levels
Change of antioxidant levels will be determined to examine effects of dark chocolate consumption vs white chocolate.
Measured: Baseline and Day 15
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2025
- Study start1 Apr 2011
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by San Diego State UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- San Diego State University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06808282
- Sponsor's protocol ID
- 658065
- Status last verified
- Feb 2026
- First submitted
- 28 Jan 2025
- Last updated
- 5 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: De-identified individual participant data collected in this study are used exclusively within the primary research group and will not be shared with other external researchers.
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Dark Chocolate on the Risk Factors of Cardiovascular Diseases
- ClinicalTrials.gov ID
- NCT06808282
- Acronym / sponsor ID
- 658065
- Conditions
- Cardiovascular Diseases
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- San Diego State UniversityUniversity, hospital or other
- Study start
- 1 Apr 2011 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 5 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiovascular disease (CVD) is the number one cause of death in the US. Epidemiologic evidence supports that antioxidant-rich diets promote health and attenuate or delay the onset of CVD. Cocoa and chocolate products have among the highest antioxidant concentrations compared to other antioxidant food sources. The objective of this study is to examine the effects of regular dark chocolate, bloomed dark chocolate, and white chocolate on cardiovascular health markers.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| White chocolate | Active comparator | Other: White chocolateSubjects consume 50g of white chocolate daily for 15 days. |
| Dark chocolate | Experimental | Other: Dark chocolateSubjects consume 50g of dark chocolate daily for 15 days. |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Generally healthy subjects
Key exclusion criteria (6 listed)
- Smoker
- Pregnant woman
- Lactose intolerance
- Required dietary supplement use
- Required medication of metabolic disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| White chocolateTo determine the effects of white chocolate consumption on risk factors of cardiovascular diseases | Other | White chocolate |
| Dark chocolateTo determine the effects of dark chocolate consumption on risk factors of cardiovascular diseases | Other | Dark chocolate |
Primary outcome
Change of systolic and diastolic blood pressure
Time frame: Baseline and Day 15
Change of systolic and diastolic blood pressure will be determined to examine effects of dark chocolate consumption vs white chocolate.
Change of skin blood flow level
Time frame: Baseline and Day 15
Change of skin blood flow level will be determined using Laser Doppler Flowmetry to examine effects of dark chocolate consumption vs white chocolate. Laser Doppler flowmetry is an optical technology widely used in research to measure blood flow. It is a non-invasive, painless technique for studying microcirculatory changes in tissue.
Change of HDL cholesterol level
Time frame: Baseline and Day 15
Change of blood cholesterol level will be determined to examine effects of dark chocolate consumption vs white chocolate.
Change of antioxidant levels
Time frame: Baseline and Day 15
Change of antioxidant levels will be determined to examine effects of dark chocolate consumption vs white chocolate.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Individual participant dataSharing planned: No. De-identified individual participant data collected in this study are used exclusively within the primary research group and will not be shared with other external researchers.
Related trials for Cardiovascular Diseases
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing White chocolate and Dark chocolate in people with Cardiovascular Diseases, run by San Diego State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of systolic and diastolic blood pressure (time frame: Baseline and Day 15). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.